LR Health & Beauty SE, a leading social commerce company for nutritional supplements and beauty products in Europe, has published its final annual report for 2025, confirming the preliminary sales and earnings figures. The company reported sales of EUR 277.1 million for the full year 2025, slightly down from EUR 289.2 million in 2024. Reported EBITDA came in at EUR 16.5 million, compared with EUR 27.3 million in the previous year, impacted by one-off effects from the reorganization of the financing structure. Normalized EBITDA for 2025 stood at EUR 22.5 million, down from EUR 32.6 million in 2024.
The publication of the annual report marks a key milestone as the company continues to execute its strategic initiatives aimed at optimizing production, logistics, and sales. Jorg Korfer, CEO of LR Health & Beauty SE, emphasized the transitional nature of 2026, stating, “The 2026 financial year is a transitional year for LR, during which we have laid the groundwork – both financially and strategically – for sustainable business growth and performance.” He added that the newly established financing structure provides the momentum to consistently pursue these initiatives in the second half of the year, with a strong focus on expanding international partnerships.
A central pillar of the company's strategy is expanding in-house production capabilities. LR is investing over EUR 2 million in a new, high-performance production line at its site in Ahlen, Germany. This investment will centralize the manufacturing of the entire 5in1 product category, including the established LR 5in1 Beauty Elixir and LR 5in1 Men’s Shot. The new production facility is designed to have an annual capacity of up to 40 million units, which not only increases efficiency but also paves the way for further product innovations in modern nutritional supplement concepts.
The company's focus on production efficiency and innovation comes at a time when the health and wellness industry is experiencing significant growth. With consumers increasingly prioritizing preventive health and convenience, LR's investment in production capacity positions it to meet rising demand. The centralization of production is expected to streamline operations, reduce costs, and enhance product quality, potentially giving LR a competitive edge in the social commerce space.
For stakeholders, the confirmed financial results provide a clearer picture of LR's performance amid strategic changes. The decline in EBITDA, while notable, is attributed to one-off financing reorganization effects rather than operational deterioration. The normalized EBITDA figure of EUR 22.5 million suggests underlying profitability remains relatively robust, supporting the company's ability to fund its strategic initiatives.
LR operates in 32 countries, offering high-quality nutritional supplements and cosmetic products. The company’s business model, which supports personal consultation and digital solutions through its “LR neo” dashboard, appeals to individuals seeking flexibility and financial independence. As the company continues to invest in production and expand internationally, it aims to strengthen its position as Europe’s leading social commerce company. The full 2025 Annual Report is now available on the company’s website at https://ir.lrworld.com.
